JP2014506928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506928A5 JP2014506928A5 JP2013556750A JP2013556750A JP2014506928A5 JP 2014506928 A5 JP2014506928 A5 JP 2014506928A5 JP 2013556750 A JP2013556750 A JP 2013556750A JP 2013556750 A JP2013556750 A JP 2013556750A JP 2014506928 A5 JP2014506928 A5 JP 2014506928A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- hormone releasing
- ileal brake
- brake hormone
- releasing compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 20
- 208000005176 Hepatitis C Diseases 0.000 claims description 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 10
- -1 asunapavir Chemical compound 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 20
- 229940088597 hormone Drugs 0.000 claims 17
- 239000005556 hormone Substances 0.000 claims 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 4
- 229960000517 boceprevir Drugs 0.000 claims 4
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 4
- ZVTDLPBHTSMEJZ-JSZLBQEHSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-JSZLBQEHSA-N 0.000 claims 4
- 235000021588 free fatty acids Nutrition 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 229920003136 Eudragit® L polymer Polymers 0.000 claims 3
- 229920003137 Eudragit® S polymer Polymers 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 210000003405 ileum Anatomy 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- HLQXYDHLDZTWDW-KAWPREARSA-N (2r,4s,5r)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(pyrazol-1-ylmethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound C([C@]1(C[C@@H]([C@@H](N1C(=O)C=1C=C(OC)C(=CC=1)C(C)(C)C)C=1SC=CN=1)COC)C(O)=O)N1C=CC=N1 HLQXYDHLDZTWDW-KAWPREARSA-N 0.000 claims 2
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 claims 2
- YFXGICNMLCGLHJ-RSKRLRQZSA-N 2,2-dimethylpropyl (2s)-2-[[[(2r,3r,4r,5r)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound C1=CC=C2C(OP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC[C@H]3O[C@H]([C@]([C@@H]3O)(C)O)N3C=4N=C(N)N=C(C=4N=C3)OC)=CC=CC2=C1 YFXGICNMLCGLHJ-RSKRLRQZSA-N 0.000 claims 2
- PVRFQJIRERYGTQ-DSQUMVBZSA-N 9-[(2s,4ar,6r,7r,7ar)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine Chemical compound C([C@H]1O2)O[P@@](=O)(OC(C)C)O[C@H]1[C@](F)(C)[C@@H]2N1C(N=C(N)N=C2OCC)=C2N=C1 PVRFQJIRERYGTQ-DSQUMVBZSA-N 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 108010090287 SCY-635 Proteins 0.000 claims 2
- VKXWOLCNTHXCLF-DXEZIKHYSA-N [(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound CC(C)C(=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(N=[N+]=[N-])O[C@H]1N1C(=O)N=C(N)C=C1 VKXWOLCNTHXCLF-DXEZIKHYSA-N 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical group N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- WVROWPPEIMRGAB-UHFFFAOYSA-N bit225 Chemical compound C1=NN(C)C=C1C1=CC=CC2=CC(C(=O)NC(N)=N)=CC=C12 WVROWPPEIMRGAB-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229960005449 daclatasvir Drugs 0.000 claims 2
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- TTZHDVOVKQGIBA-IAAJYNJHSA-N propan-2-yl (2s)-2-[[[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)COP(=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IAAJYNJHSA-N 0.000 claims 2
- DEKOYVOWOVJMPM-RLHIPHHXSA-N setrobuvir Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(O)=C(C1=O)C=1NC2=CC=C(C=C2S(=O)(=O)N=1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 DEKOYVOWOVJMPM-RLHIPHHXSA-N 0.000 claims 2
- 229960002091 simeprevir Drugs 0.000 claims 2
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 claims 2
- 229960002063 sofosbuvir Drugs 0.000 claims 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- JXQUAHHUSMJUFV-HZPZRMRQSA-N 9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1([C@@H]2CCO[P@](O2)(=O)COCCN2C=3N=CN=C(C=3N=C2)N)=CC=CC(Cl)=C1 JXQUAHHUSMJUFV-HZPZRMRQSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical group NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 1
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005338 clevudine Drugs 0.000 claims 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960000366 emtricitabine Drugs 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229940124828 glucokinase activator Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940097709 hepsera Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 claims 1
- 229960002480 nitazoxanide Drugs 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229950001452 pradefovir Drugs 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 241000711557 Hepacivirus Species 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940099268 synthroid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/932,633 US9757346B2 (en) | 2008-09-03 | 2011-03-02 | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
| US12/932,633 | 2011-03-02 | ||
| US201161480788P | 2011-04-29 | 2011-04-29 | |
| US61/480,788 | 2011-04-29 | ||
| US201161514174P | 2011-08-02 | 2011-08-02 | |
| US61/514,174 | 2011-08-02 | ||
| US201161551638P | 2011-10-26 | 2011-10-26 | |
| US61/551,638 | 2011-10-26 | ||
| PCT/US2012/026561 WO2012118712A2 (en) | 2011-03-02 | 2012-02-24 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228965A Division JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506928A JP2014506928A (ja) | 2014-03-20 |
| JP2014506928A5 true JP2014506928A5 (enExample) | 2015-04-02 |
| JP6253991B2 JP6253991B2 (ja) | 2017-12-27 |
Family
ID=46758432
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556750A Expired - Fee Related JP6253991B2 (ja) | 2011-03-02 | 2012-02-24 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2017228965A Pending JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2019033502A Pending JP2019123716A (ja) | 2011-03-02 | 2019-02-27 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228965A Pending JP2018065840A (ja) | 2011-03-02 | 2017-11-29 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
| JP2019033502A Pending JP2019123716A (ja) | 2011-03-02 | 2019-02-27 | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9370528B2 (enExample) |
| EP (1) | EP2680859B1 (enExample) |
| JP (3) | JP6253991B2 (enExample) |
| KR (4) | KR20190060879A (enExample) |
| CN (2) | CN110152000A (enExample) |
| AU (3) | AU2012223528A1 (enExample) |
| BR (1) | BR112013022391A2 (enExample) |
| EA (1) | EA201391262A1 (enExample) |
| IL (2) | IL228259B (enExample) |
| WO (1) | WO2012118712A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9155772B2 (en) | 2008-12-08 | 2015-10-13 | Philip Morris Usa Inc. | Soft, chewable and orally dissolvable and/or disintegrable products |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| EP2630491A4 (en) | 2010-10-19 | 2014-08-27 | Elcelyx Therapeutics Inc | THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS |
| US9370528B2 (en) | 2011-03-02 | 2016-06-21 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection |
| US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| JP6203816B2 (ja) | 2012-03-29 | 2017-09-27 | セラバイオーム，エルエルシー | 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤 |
| HUE044605T2 (hu) * | 2012-11-16 | 2019-11-28 | Univ College Cardiff Consultants Ltd | RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke |
| AU2014205553A1 (en) * | 2013-01-08 | 2015-07-09 | Volant Holdings Gmbh | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| AU2014236559B2 (en) | 2013-03-14 | 2020-03-12 | Julie HUGHES | Cholestosome vesicles for incorporation of molecules into chylomicrons |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN111494375A (zh) * | 2013-03-15 | 2020-08-07 | 雪松-西奈医学中心 | 由产甲烷菌引起或与之相关的疾病和病状的诊断、选择和治疗方法 |
| IL247301B (en) * | 2014-02-20 | 2022-07-01 | Vaxart Inc | Formulations for small intestinal delivery |
| WO2016011335A1 (en) * | 2014-07-17 | 2016-01-21 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| EP3307239B1 (en) | 2015-06-12 | 2020-09-16 | Vaxart, Inc. | Formulations for small intestinal delivery of rsv and norovirus antigens |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
| US11400078B2 (en) * | 2016-04-11 | 2022-08-02 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| PT3442580T (pt) | 2016-04-11 | 2020-12-23 | Genfit | Métodos de tratamento para doenças colestáticas e fibróticas |
| WO2017203367A2 (en) * | 2016-05-22 | 2017-11-30 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| WO2018090049A1 (en) * | 2016-11-14 | 2018-05-17 | The Brigham And Women's Hospital, Inc. | Estrogen sensing through gper1 regulates normal and malignant liver growth |
| CA3046158A1 (en) | 2017-01-27 | 2018-08-02 | Genfit | Pharmaceutical compositions for combination therapy |
| IL268751B (en) * | 2017-03-13 | 2022-08-01 | Genfit | Pharmaceutical preparations for combined treatment |
| GB2571749A (en) * | 2018-03-07 | 2019-09-11 | Anabio Tech Limited | A method inducing satiety in a mammal |
| WO2020120519A1 (en) | 2018-12-10 | 2020-06-18 | Aphaia Pharma Ag | Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines |
| ES2906316T3 (es) | 2018-12-10 | 2022-04-18 | Aphaia Ip Ag | Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas |
| CN109568284B (zh) * | 2018-12-29 | 2020-04-24 | 广东中润药物研发有限公司 | 一种替诺福韦艾拉酚胺肠溶片及其制备方法 |
| CN110478357A (zh) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| CN116096352A (zh) | 2020-06-10 | 2023-05-09 | 阿帕亚知识产权公司 | 含有与胶凝剂组合的多个剂型的肠因子释放物质的药物组合物 |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
| JP7109827B1 (ja) * | 2021-11-16 | 2022-08-01 | 株式会社ハニック・ホワイトラボ | 抗ウイルス剤 |
| JP2025529259A (ja) * | 2022-09-01 | 2025-09-04 | エイチエルビー ジェネックス インク | スーパーオキシドディスムターゼを発現するバチルス種菌株、バチルス種菌株胞子及び／又はスーパーオキシドディスムターゼ並びにその線維化疾患の予防又は治療のための用途 |
| WO2025119939A1 (en) | 2023-12-03 | 2025-06-12 | Aphaia Pharma Ag | Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions |
| LU103233B1 (en) | 2023-12-21 | 2025-06-24 | Aphaia Ip Ag | Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions |
| US12599544B2 (en) | 2024-05-09 | 2026-04-14 | Alsteni Medical, Inc. | Intraoral gastrointestinal access device and related methods |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51133489A (en) * | 1975-05-14 | 1976-11-19 | Tokyo Daigaku | Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities |
| US4544550A (en) | 1982-10-05 | 1985-10-01 | Rodolfo Almanzor Y | Method for the treatment of diabetes |
| US5194464A (en) | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
| US5769793A (en) | 1989-09-08 | 1998-06-23 | Steven M. Pincus | System to determine a relative amount of patternness |
| US5120563A (en) * | 1989-12-21 | 1992-06-09 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
| JPH07503615A (ja) * | 1992-02-04 | 1995-04-20 | カイロン コーポレイション | 肝炎療剤 |
| US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
| US5976548A (en) | 1994-11-08 | 1999-11-02 | Viva America Marketing, Inc. | Nutritional supplement composition and use |
| CN1194831A (zh) * | 1997-04-01 | 1998-10-07 | 李春华 | 利巴韦林大输液系列制剂 |
| TWI277424B (en) * | 1998-05-15 | 2007-04-01 | Schering Corp | Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2001093683A1 (en) | 2000-06-07 | 2001-12-13 | Watson Pharmaceuticals, Inc. | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
| CA2483827C (en) | 2002-04-29 | 2012-01-24 | Amir H. Shojaei | Pharmaceutical formulations with improved bioavailability |
| US20040062778A1 (en) | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
| EP1462116A1 (en) | 2003-03-29 | 2004-09-29 | Villitech SARL | Composition for treating the gastrointestinal tract |
| WO2005110455A2 (en) | 2004-05-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating hepatitis virus infection |
| WO2006034463A2 (en) | 2004-09-23 | 2006-03-30 | Herbalife International, Inc. | Herbal supplement to support weight loss |
| AU2005289710A1 (en) | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
| US20060093592A1 (en) | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
| MX2007015085A (es) * | 2005-05-31 | 2008-01-17 | Novartis Ag | Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis. |
| JP2007001945A (ja) | 2005-06-24 | 2007-01-11 | Tsuneo Ozeki | 癌治療剤 |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| AU2006288703B2 (en) | 2005-09-06 | 2011-09-22 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| CN101646419A (zh) | 2006-11-08 | 2010-02-10 | 诺瓦瓦克斯股份有限公司 | 制备多相药物组合物的固体剂型的方法 |
| US7951789B2 (en) * | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20070172525A1 (en) | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| EP2300031B1 (en) | 2008-05-05 | 2017-09-20 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
| WO2010027498A2 (en) * | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
| US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
| BRPI0920170A2 (pt) | 2008-10-17 | 2016-06-21 | Metabolex Inc | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| WO2010093789A2 (en) | 2009-02-12 | 2010-08-19 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| US9023408B2 (en) | 2009-03-04 | 2015-05-05 | Meyer Nutriceuticals Llc | Composition and method for control of diabetes |
| RU2410108C1 (ru) | 2009-08-03 | 2011-01-27 | Государственное образовательное учреждение высшего профессионального образования "Орловский государственный технический университет" (ОрелГТУ) | Способ скармливания пробиотика поросятам-сосунам |
| US8367418B2 (en) | 2009-10-23 | 2013-02-05 | Therasyn Sensors, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US8999721B2 (en) | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20140294951A1 (en) | 2011-10-26 | 2014-10-02 | Joseph M. Fayad | Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D |
| US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| US9370528B2 (en) | 2011-03-02 | 2016-06-21 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection |
| JP6203816B2 (ja) | 2012-03-29 | 2017-09-27 | セラバイオーム，エルエルシー | 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤 |
| AU2014205553A1 (en) | 2013-01-08 | 2015-07-09 | Volant Holdings Gmbh | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
-
2012
- 2012-02-24 US US14/002,642 patent/US9370528B2/en active Active
- 2012-02-24 KR KR1020197014958A patent/KR20190060879A/ko not_active Ceased
- 2012-02-24 KR KR1020207000460A patent/KR20200006177A/ko not_active Ceased
- 2012-02-24 JP JP2013556750A patent/JP6253991B2/ja not_active Expired - Fee Related
- 2012-02-24 WO PCT/US2012/026561 patent/WO2012118712A2/en not_active Ceased
- 2012-02-24 EP EP12752890.9A patent/EP2680859B1/en active Active
- 2012-02-24 AU AU2012223528A patent/AU2012223528A1/en not_active Abandoned
- 2012-02-24 BR BR112013022391A patent/BR112013022391A2/pt active Search and Examination
- 2012-02-24 KR KR1020187030127A patent/KR102198749B1/ko not_active Expired - Fee Related
- 2012-02-24 CN CN201910281848.9A patent/CN110152000A/zh active Pending
- 2012-02-24 EA EA201391262A patent/EA201391262A1/ru unknown
- 2012-02-24 KR KR1020137026087A patent/KR20140147657A/ko not_active Ceased
- 2012-02-24 CN CN201280021792.XA patent/CN103635196B/zh not_active Expired - Fee Related
-
2013
- 2013-09-02 IL IL228259A patent/IL228259B/en active IP Right Grant
-
2016
- 2016-05-24 US US15/162,941 patent/US9730951B2/en active Active
-
2017
- 2017-04-25 AU AU2017202713A patent/AU2017202713A1/en not_active Abandoned
- 2017-06-15 US US15/624,275 patent/US10245277B2/en active Active
- 2017-11-29 JP JP2017228965A patent/JP2018065840A/ja active Pending
-
2018
- 2018-03-29 IL IL258450A patent/IL258450A/en unknown
-
2019
- 2019-02-27 JP JP2019033502A patent/JP2019123716A/ja active Pending
- 2019-03-20 AU AU2019201917A patent/AU2019201917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6253991B2 (ja) | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 | |
| CN100536853C (zh) | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 | |
| JP6360607B2 (ja) | ２つの抗ウイルス化合物の組合せ製剤 | |
| KR101962522B1 (ko) | 두 항바이러스 화합물의 병용 제형물 | |
| JP2017528471A (ja) | 肝疾患を処置する方法 | |
| US9415046B2 (en) | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods | |
| JP2013082726A (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| CN114025760B (zh) | 改进的用eyp001的治疗 | |
| US20260034191A1 (en) | Larazotide formulations | |
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| JP2017536380A5 (enExample) | ||
| WO2022142945A1 (zh) | 一种用于治疗或预防病毒性肝炎的药物组合物及其应用 | |
| TW202126304A (zh) | 使用核心蛋白異位調節劑治療hbv感染之方法 | |
| WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
| Sandmann et al. | HBV cure—The light at the end of the tunnel? | |
| HK40010279A (en) | Compositions for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection | |
| TW200811138A (en) | Pharmaceuticals | |
| HK1220392B (zh) | 两种抗病毒化合物的复方制剂 |